drugset / Trial / NCT05903937
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with percutaneous hepatic perfusion in patients with liver metastases (but not restricted to) of malignant melanoma
Timeline
- Start
- 2023-12-31
- Primary completion
- 2024-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous Tumor Infiltrating Lymphocytes | Cell therapy | — | Other |
| Background | Melphalan | Small molecule | — | Other |
| Background | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |